Cumberland Pharmaceuticals Inc
A specialty biopharmaceutical company that develops and sells branded prescription medicines for hospitals, including Acetadote, an injection used to treat acetaminophen (Tylenol) poisoning, and Caldolor, an intravenous ibuprofen for pain and fever. Founded in 1999 in Nashville, Tennessee, it takes its name from the Cumberland River that runs through the city. Its Acetadote was the first injectable product approved in the United States for treating acetaminophen overdose.
Granted 870.0K · Bought 31.7K · Sold 9.5K
Granted 24.5K · Sold 116.8K
Granted 15.6K · Sold 156.2K
Granted 115.0K · Bought 5.9K · Sold 3.8K
Granted 32.8K · Bought 86.3K
Granted 58.0K · Bought 29.7K
Granted 317.5K · Bought 5.0K · Sold 1.7K
Granted 36.0K · Bought 67.4K
Granted 10.3K · Bought 43.0K
Granted 18.3K · Bought 18.6K
Granted 45.0K
Granted 41.8K
Granted 13.3K · Bought 12.1K
Granted 20.0K · Bought 3.8K
Granted 11.7K · Sold 8.0K
Granted 15.0K · Bought 4.0K
Granted 6.3K
Granted 52.5K · Sold 175.6K
Granted 13.6K · Sold 120.4K
Granted 3.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kazimi A JChairman and CEO, Director, 10% owner · 928 transactions | — | 5.70M | 870.0K | 31.7K | 9.5K |
| Greer Lawrence WDirector · 7 transactions | — | 583.3Kas of Mar 2012 | 24.5K | — | 116.8K |
| Marstiller Jean WSr. VP & Corp. Secretary · 6 transactions | — | 440.8Kas of Nov 2012 | 15.6K | — | 156.2K |
| Edwards RobertDirector · 9 transactions | — | 417.6Kas of Mar 2014 | 115.0K | 5.9K | 3.8K |
| Krogulski KennethDirector · 905 transactions | — | 302.3K | 32.8K | 86.3K | — |
| Cearnal Martin ESr VP/Chief Commercial Officer, Director · 196 transactions | — | 163.5Kas of Mar 2022 | 58.0K | 29.7K | — |
| Pavliv LeoSVP and Chief Development Off. · 32 transactions | — | 129.6Kas of May 2022 | 317.5K | 5.0K | 1.7K |
| Jacobs Joey ADirector · 52 transactions | — | 98.4Kas of Jan 2023 | 36.0K | 67.4K | — |
| Galante Joseph CDirector · 505 transactions | — | 63.7K | 10.3K | 43.0K | — |
| Jones JamesDirector · 735 transactions | — | 46.9K | 18.3K | 18.6K | — |
| Greene Rick ScottChief Financial Officer · 5 transactions | — | 45.0Kas of Mar 2015 | 45.0K | — | — |
| Herman James LVP and Chief Compliance Office · 21 transactions | — | 38.3Kas of Mar 2024 | 41.8K | — | — |
| Young CarolineDirector · 1039 transactions | — | 35.1K | 13.3K | 12.1K | — |
| Hamm John M.VP Chief Financial Officer · 5 transactions | — | 20.1Kas of Mar 2025 | 20.0K | 3.8K | — |
| Anthony Todd M.Vice Pres Organizational Dev · 1 transaction | — | 16.3Kas of Mar 2024 | — | — | — |
| Griggs JonathanDirector · 13 transactions | — | 14.8Kas of Mar 2021 | 11.7K | — | 8.0K |
| Bonner MichaelChief Financial Officer · 20 transactions | — | 11.7Kas of May 2021 | 15.0K | 4.0K | — |
| Brown Martin S JRDirector · 4 transactions | — | 10.3K | 6.3K | — | — |
| Bitterman Chris T.Vice Pres Sales & Marketing · 1 transaction | — | 4.7Kas of Mar 2024 | — | — | — |
| Lawrence Thomas RDirector · 28 transactions | — | 0as of Apr 2017 | 52.5K | — | 175.6K |
| Bernard Gordon RDirector · 88 transactions | — | 0as of Dec 2019 | 13.6K | — | 120.4K |
| Lowrance David LVice President and CFO · 2 transactions | — | 0as of Apr 2011 | 3.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -284.6K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.